A Phase 3 interventional study of Prevnar 13™ and Pneumovax™ 23 in Pneumococcal Infections, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 17th largest by enrollment, is one of 2 that started in 2014, is one of 19 in phase 3, and was the 24th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 2 started in 2014.
This study's enrollment of 400 is close to the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 26th largest by enrollment, is one of 3 that started in 2014, is one of 31 in phase 3, and was the 10th registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and immunogenicity of sequential administration of Prevnar 13™ and Pneumovax™ 23 in healthy participants 50 years of age and older. The primary hypotheses in the study are that 1) geometric mean titers (GMTs) to pneumococcal serotypes 22F and 33F (serotypes in Pneumovax™ 23 but not in Prevnar 13™) as measured at Week 12 are superior in participants administered Prevnar 13™ on Day 1 and Pneumovax™ 23 at Week 8, as compared with participants administered Prevnar 13™ on Day 1 and placebo at Week 8 and 2) GMTs to pneumococcal serotypes shared by the two vaccines as measured at Week 12 are non-inferior in participants administered Prevnar 13™ followed by Pneumovax™ 23 as compared with participants administered Prevnar 13™ followed by placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
Biological: Prevnar 13™ · Biological: Pneumovax™ 23 · Biological: Placebo
Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
Biological: Prevnar 13™ · Biological: Pneumovax™ 23 · Biological: Placebo
Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
Injections are to be administered into the deltoid muscle of the upper arm.
Percentage of Participants With an Adverse Event (AE)
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to 14 days after any vaccination (Up to 28 weeks)
Percentage of Participants With an Injection-site Adverse Event
An injection site adverse event (AE) includes the following AEs at the injection site: redness, swelling, and pain/tenderness.
Time frame: Up to 14 days after any vaccination (Up to 28 weeks)
Percentage of Participants With a Systemic Adverse Event
Systemic adverse events (AEs) include, but are not restricted to the following AE terms: muscle pain, joint pain, headache, and tiredness.
Time frame: Up to 14 days after any vaccination (Up to 28 weeks)
Percentage of Participants With a Serious Adverse Event (SAE)
A serious adverse event (SAE) is any adverse event occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; or is associated with an overdose.
Time frame: Up to 30 weeks
Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) or Vaccine-related Death
A serious adverse event (SAE) is any adverse event occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; or is associated with an overdose. The investigator determined whether the SAE or death was related to vaccine treatment.
Time frame: Up to 30 weeks
Percentage of Participants Who Discontinued Vaccination Due to an Adverse Event
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to 26 weeks
Geometric Mean Titers to Pneumococcal Serotypes 22F and 33F at Week 12
Vaccine-induced functional antibodies to serotypes 22F and 33F, which are unique to PNEUMOVAX™ 23, were measured by the multiplex opsonophagocytic activity 4 (MOPA-4) assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
Time frame: Week 12
Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, at Week 12
Vaccine-induced functional antibodies to serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, which are contained in both Prevnar 13™ and PNEUMOVAX™ 23, were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
Time frame: Week 12
Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 8
Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
Time frame: Week 8
Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 26
Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
Time frame: Week 26
Geometric Mean Titers to Pneumococcal Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F at Week 30
Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
Time frame: Week 30
| Milestone | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Started | 200 | 200 |
| Vaccination 2 | 188 | 185 |
| Vaccination 3 | 172 | 164 |
| Completed | 172 | 162 |
| Not completed | 28 | 38 |
| Withdrew: Adverse event | 5 | 5 |
| Withdrew: Lost to follow-up | 5 | 5 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Participant moved | 1 | 0 |
| Withdrew: Withdrawal by subject | 13 | 28 |
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| Percentage of participants | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Percentage of Participants With an Adverse Event (AE) | 89.9 | 84.4 |
An injection site adverse event (AE) includes the following AEs at the injection site: redness, swelling, and pain/tenderness.
| Percentage of participants | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Percentage of Participants With an Injection-site Adverse Event | 86.4 | 77.9 |
Systemic adverse events (AEs) include, but are not restricted to the following AE terms: muscle pain, joint pain, headache, and tiredness.
| Percentage of participants | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Percentage of Participants With a Systemic Adverse Event | 76.8 | 74.4 |
A serious adverse event (SAE) is any adverse event occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; or is associated with an overdose.
| Percentage of participants | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Percentage of Participants With a Serious Adverse Event (SAE) | 4.5 | 5.5 |
A serious adverse event (SAE) is any adverse event occurring at any dose or during any use of Sponsor's product that: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is another important medical event; is a cancer; or is associated with an overdose. The investigator determined whether the SAE or death was related to vaccine treatment.
| Percentage of participants | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) or Vaccine-related Death | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| Percentage of participants | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Percentage of Participants Who Discontinued Vaccination Due to an Adverse Event | 2.5 | 2.5 |
Vaccine-induced functional antibodies to serotypes 22F and 33F, which are unique to PNEUMOVAX™ 23, were measured by the multiplex opsonophagocytic activity 4 (MOPA-4) assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
| Titer | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Serotype 22F | 1766.3 (1303.2 to 2394.1) | 39.0 (28.3 to 53.7) |
| Serotype 33F | 10413.0 (8178.9 to 13257.4) | 1189.9 (898.6 to 1575.6) |
Vaccine-induced functional antibodies to serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, which are contained in both Prevnar 13™ and PNEUMOVAX™ 23, were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
| Titer | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Serotype 1 | 81.7 (60.4 to 110.7) | 57.1 (41.1 to 79.3) |
| Serotype 3 | 43.4 (33.7 to 55.9) | 17.5 (13.5 to 22.5) |
| Serotype 4 | 1079.3 (885.7 to 1315.2) | 780.0 (629.1 to 967.1) |
| Serotype 5 | 198.6 (145.6 to 271.0) | 148.4 (107.9 to 204.1) |
| Serotype 6B | 1956.9 (1575.3 to 2431.0) | 1148.1 (889.0 to 1482.6) |
| Serotype 7F | 2250.8 (1889.3 to 2681.5) | 1751.8 (1422.4 to 2157.6) |
| Serotype 9V | 1472.3 (1190.9 to 1820.2) | 1017.6 (790.8 to 1309.4) |
| Serotype 14 | 2106.8 (1689.6 to 2627.0) | 1945.0 (1572.9 to 2405.1) |
| Serotype 18C | 2101.9 (1732.6 to 2550.0) | 1587.1 (1259.1 to 2000.5) |
| Serotype 19A | 1785.8 (1506.1 to 2117.6) | 1425.9 (1164.7 to 1745.8) |
| Serotype 19F | 1051.0 (862.1 to 1281.3) | 627.2 (490.5 to 802.2) |
| Serotype 23F | 1155.6 (867.2 to 1539.9) | 716.9 (521.1 to 986.3) |
Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
| Titer | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Serotype 1 | 100.7 (50.5 to 200.9) | 54.7 (27.5 to 108.5) |
| Serotype 3 | 52.8 (32.2 to 86.5) | 27.8 (16.6 to 46.5) |
| Serotype 4 | 1075.7 (671.4 to 1723.5) | 1051.0 (696.0 to 1587.0) |
| Serotype 5 | 350.5 (193.2 to 636.1) | 143.9 (77.7 to 266.3) |
| Serotype 6A | 3945.3 (2301.9 to 6762.2) | 4024.1 (2622.8 to 6174.1) |
| Serotype 6B | 2154.2 (1325.4 to 3501.3) | 1259.7 (707.3 to 2243.5) |
| Serotype 7F | 3830.5 (2654.6 to 5527.2) | 2064.0 (1287.4 to 3309.0) |
| Serotype 9V | 1555.6 (988.7 to 2447.6) | 1606.5 (1064.5 to 2424.6) |
| Serotype 14 | 2417.0 (1547.8 to 3774.1) | 1586.4 (901.6 to 2791.3) |
| Serotype 18C | 1890.8 (1313.3 to 2722.1) | 1563.7 (857.8 to 2850.3) |
| Serotype 19A | 2102.3 (1567.6 to 2819.5) | 1819.8 (1300.2 to 2547.0) |
| Serotype 19F | 1039.4 (646.0 to 1672.2) | 640.4 (378.1 to 1084.9) |
| Serotype 22F | 116.4 (54.9 to 246.8) | 30.9 (16.6 to 57.5) |
| Serotype 23F | 1245.8 (656.9 to 2362.5) | 779.8 (414.3 to 1467.8) |
| Serotype 33F | 1515.4 (914.3 to 2511.5) | 1984.0 (1207.9 to 3259.0) |
Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
| Titer | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Serotype 1 | 39.7 (20.4 to 77.4) | 18.9 (10.7 to 33.3) |
| Serotype 3 | 19.6 (12.0 to 32.1) | 9.2 (6.2 to 13.7) |
| Serotype 4 | 737.1 (451.9 to 1202.1) | 788.4 (535.3 to 1161.1) |
| Serotype 5 | 114.4 (58.5 to 223.4) | 65.6 (36.2 to 118.8) |
| Serotype 6A | 1843.2 (1111.0 to 3057.8) | 1152.9 (655.0 to 2029.3) |
| Serotype 6B | 1157.0 (639.0 to 2094.7) | 1125.1 (689.7 to 1835.6) |
| Serotype 7F | 1204.9 (832.1 to 1744.8) | 770.7 (499.5 to 1189.2) |
| Serotype 9V | 698.2 (437.7 to 1113.8) | 806.5 (500.9 to 1298.7) |
| Serotype 14 | 1458.2 (949.2 to 2240.1) | 1373.9 (879.5 to 2146.1) |
| Serotype 18C | 914.2 (594.3 to 1406.2) | 691.1 (383.1 to 1246.7) |
| Serotype 19A | 1024.3 (749.4 to 1400.1) | 806.3 (539.3 to 1205.6) |
| Serotype 19F | 563.7 (344.0 to 923.7) | 228.9 (126.1 to 415.5) |
| Serotype 22F | 1228.3 (733.3 to 2057.4) | 45.2 (23.5 to 86.7) |
| Serotype 23F | 653.8 (315.8 to 1353.4) | 366.6 (195.9 to 685.9) |
| Serotype 33F | 4672.8 (2968.8 to 7354.7) | 1151.4 (660.4 to 2007.6) |
Vaccine-induced functional antibodies were measured by the MOPA-4 assay, which is based on the ability of antibody in the serum to initiate killing of bacterial pneumococci.
| Titer | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Serotype 1 | 36.0 (23.2 to 55.9) | 43.4 (28.8 to 65.5) |
| Serotype 3 | 13.9 (10.2 to 18.9) | 32.8 (23.8 to 45.2) |
| Serotype 4 | 803.6 (601.2 to 1074.2) | 1060.0 (796.2 to 1411.3) |
| Serotype 5 | 81.5 (51.1 to 130.0) | 117.3 (83.5 to 164.9) |
| Serotype 6A | 1673.9 (1141.5 to 2454.5) | 1782.7 (1255.1 to 2532.1) |
| Serotype 6B | 1330.3 (911.8 to 1940.8) | 1343.6 (993.3 to 1817.3) |
| Serotype 7F | 877.7 (683.3 to 1127.5) | 1248.4 (955.3 to 1631.4) |
| Serotype 9V | 628.9 (444.3 to 890.4) | 1134.8 (841.4 to 1530.5) |
| Serotype 14 | 1762.9 (1257.3 to 2471.7) | 1963.3 (1441.9 to 2673.4) |
| Serotype 18C | 779.3 (582.9 to 1041.8) | 1125.6 (843.5 to 1502.1) |
| Serotype 19A | 845.5 (649.5 to 1100.6) | 1256.1 (1027.9 to 1535.0) |
| Serotype 19F | 349.1 (236.9 to 514.5) | 880.8 (663.9 to 1168.6) |
| Serotype 22F | 1124.7 (751.7 to 1682.9) | 982.1 (642.6 to 1501.0) |
| Serotype 23F | 574.3 (367.6 to 897.2) | 755.6 (521.6 to 1094.4) |
| Serotype 33F | 5917.9 (4199.6 to 8339.4) | 7853.5 (5521.3 to 11171.0) |
Collected over Up to 30 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | 1/200 (0.5%) | 9/200 (4.5%) | 177/200 (88.5%) |
| Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 | 0/200 (0%) | 11/200 (5.5%) | 165/200 (82.5%) |
| Event | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Myocardial infarctionCardiac disorders | 2/200 | 0/200 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/200 | 2/200 |
| Cerebrovascular accidentNervous system disorders | 0/200 | 2/200 |
| Angina pectorisCardiac disorders | 1/200 | 0/200 |
| Atrial fibrillationCardiac disorders | 1/200 | 0/200 |
| Coronary artery diseaseCardiac disorders | 1/200 | 0/200 |
| PancreatitisGastrointestinal disorders | 0/200 | 1/200 |
| PneumoniaInfections and infestations | 0/200 | 1/200 |
| Gastrointestinal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/200 | 1/200 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/200 | 1/200 |
| Event | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 |
|---|---|---|
| Injection site painGeneral disorders | 168/200 | 151/200 |
| MyalgiaMusculoskeletal and connective tissue disorders | 123/200 | 115/200 |
| Injection site swellingGeneral disorders | 111/200 | 78/200 |
| FatigueGeneral disorders | 100/200 | 89/200 |
| Injection site erythemaGeneral disorders | 99/200 | 72/200 |
| HeadacheNervous system disorders | 78/200 | 60/200 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 58/200 | 55/200 |
| Age, Continuous(Years) | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 | Total |
|---|---|---|---|
| Mean | 64.1 ± 8.6 | 64.2 ± 8.9 | 64.2 ± 8.7 |
| Sex: Female, Male(Participants) | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 | Total |
|---|---|---|---|
| Female | 112 | 107 | 219 |
| Male | 88 | 93 | 181 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 | Total |
|---|---|---|---|
| Hispanic or Latino | 40 | 35 | 75 |
| Not Hispanic or Latino | 158 | 164 | 322 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo | Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 4 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 14 | 23 | 37 |
| White | 176 | 163 | 339 |
| More than one race | 7 | 8 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Aug 2014 to primary completion in Jul 2015, 10 months.
Results were first posted in Feb 2020, 4 years 6 months after primary completion. A results delay was requested in Jun 2016.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 10 months is below that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: 13-valent pneumococcal vaccine · 23-valent pneumococcal capsular polysaccharide vaccine